Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
NCT02157181
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
89
Enrollment
OTHER
Sponsor class
Conditions
Hairy Cell Leukemia (HCL)
Interventions
DRUG:
2CdA +/- Rituximab
Sponsor
Jurgen Barth